Rare Sugars Release Glucagon-Like Peptide-1 and Suppress Food Intake in Mice

The GLP-1 Angle in Rare Sugars

If you formulate with D-allulose, this paper gives you another mechanism to talk about. Researchers gave mice a single oral dose of D-allulose and watched active GLP-1 rise in portal plasma. They also watched food intake drop. When they blocked the GLP-1 receptor, that food intake effect disappeared.

The study appears in Nutrients. DOI: 10.3390/nu17071221.

Background: Rare Sugars as Functional Ingredients

Rare sugars occur naturally in small quantities. They offer sweetness with low calorie content. That makes them candidates for next-generation functional sugars. The researchers focused on D-allulose, a rare sugar already used in some food and beverage applications.

This study adds a new layer to that story. It is not just about taste or calories. It is about gut hormone signaling.

What the Study Did

The team used mice and dosed them by oral gavage. They tested 1 g/kg and 3 g/kg of D-allulose. Then they measured active GLP-1 in portal plasma. They also measured short-term food intake.

Then came the clever part. They gave a GLP-1 receptor antagonist called exendin(9-39) alongside D-allulose. That blocker cancelled the food intake suppression. In other words, the reduced feeding was not accidental. It depended on GLP-1 receptor signaling.

This is an acute experiment. Single dose. Direct measurement. That makes the result easier to interpret than a long feeding study with many variables.

Key Findings

Both doses raised active GLP-1 significantly. The effect on food intake was dose-dependent. More D-allulose meant stronger suppression. And the receptor-blocking experiment confirmed the mechanism.

Dose of D-allulose (single oral gavage)	Portal active GLP-1	Short-term food intake
1 g/kg	Significantly increased	Suppressed
3 g/kg	Significantly increased	More strongly suppressed, dose-dependent

The paper’s authors conclude that rare sugars like D-allulose have potential as functional food ingredients. They point to possible roles in preventing overeating and supporting blood glucose control.

What It Means for Manufacturers

For ingredient buyers, the GLP-1 response is a useful data point. D-allulose is already attractive because of its sweetness and low calorie load. This study suggests it could also contribute to satiety signals in the gut.

That opens product positioning possibilities. Think meal replacement bars, reduced-sugar desserts, or beverages designed for post-meal glucose support. D-allulose can do more than replace sugar. It may act on pathways related to appetite and glucose control.

But keep the context clear. This is mouse data. The doses used were acute oral gavage doses, not human eating patterns. You cannot translate 1 g/kg directly to a serving size in a protein bar.

Use this study as mechanistic evidence. It helps explain why D-allulose behaves differently from standard sweeteners. It does not support a health claim on its own.

FAQ

Does D-allulose work this way in humans?

This study used mice. Human data is not included in this paper. The GLP-1 mechanism is worth watching, but clinical confirmation is still needed.

Why did the researchers use exendin(9-39)?

Exendin(9-39) is a GLP-1 receptor antagonist. It blocks the receptor so GLP-1 cannot send its normal signal. When D-allulose no longer suppressed food intake after that blocker, the researchers knew GLP-1 signaling was required.

What dose did the study use?

1 g/kg and 3 g/kg body weight, given once by oral gavage. Those are animal doses. Do not calculate them into human serving sizes.

D-allulose already earns its place in formulations for taste and calorie reduction. This paper adds a hormone-level effect: it releases active GLP-1 and suppresses food intake in mice through a GLP-1 receptor pathway. That is exactly the kind of mechanistic evidence formulators can track. The next meaningful milestone will be human data, not another mouse study.